 | Up a level |
Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x
Koeberle, Dieter; Betticher, Daniel; Von Moos, Roger; Dietrich, Daniel; Brauchli, Peter; Baertschi, Daniela; Matter-Walstra, Klazien; Winterhalder, Ralph; Borner, Markus; Anchisi, Sandro; Moosmann, Peter; Kollár, Attila; Saletti, Piercarlo; Roth, Arnaud; Frueh, Martin; Kueng, Marc; Popescu, Razvan; Schacher, Sabina; Hess, Viviane and Herrmann, Richard (2013). O-0028 Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial. Annals of oncology, 24(Suppl 4), iv22-iv22. Oxford University Press 10.1093/annonc/mdt201.28
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Ribi, Karin; Koeberle, Dieter; Schuller, Jan C; Honegger, Hanspeter; Roth, Arnaud; Hess, Viviane; Moosmann, Peter; von Moos, Roger; Borner, Markus; Lombriser, Norbert; Pestalozzi, Bernhard; Ruhstaller, Thomas (2009). Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Supportive care in cancer, 17(8), pp. 1109-1116. Berlin: Springer 10.1007/s00520-008-0570-6
